Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis Authors: Chiara Lupia, Daniela Pastore, Antonio Giacalone, Federica Marrelli, Lucia Novelli, Debbie Riccelli, Angelantonio Maglio, Giuseppe Armentaro, Angela Sciacqua, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia Published: 2026 ABSTRACT AbstractIntroductionSingle-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic or experience exacerbations despite dual bronchodilation. However, real-world evidence on its ability to achieve multidimensional “disease stability”, integrating symptoms, lung function, and exacerbation outcomes, remains limited. The aim of our study was therefore to evaluate, in a real-world cohort of exacerbating patients with COPD, the effects of once-daily FF/UMEC/VI on lung function, respiratory symptoms, health status, and exacerbation rates over 12 months.MethodsThis retrospective single-center study included 86 adults with COPD treated with FF/UMEC/VI 92/55/22 µg at the Respiratory Unit of “Magna Graecia” University Hospital (Catanzaro, Italy). Lung function tests (forced expiratory volume in the first second, FEV1; forced vital capacity, FVC; forced mid-expiratory flow between 25% and 75% of FVC, FEF25–75; residual volume, RV; total lung capacity, TLC; corrected single-breath diffusion lung capacity for carbon monoxide, DLCOcSB) were performed at baseline and after 12 months. Symptoms and health status were assessed using the COPD Assessment Test (CAT). Moderate and severe exacerbations were recorded within the previous 12 months and 12 months after treatment initiation. Safety and tolerability were monitored via monthly phone follow-up.ResultsEighty-six patients were included (24 women, 28%; 62 men, 72%), with a mean age of 72.29 ± 9.20 years and a median BMI of 30 (26.00–36.50) kg/m2. After 12 months of FF/UMEC/VI, lung function significantly improved: FEV1 increased from 1.46 ± 0.51 l to 1.61 ± 0.60 l (p < 0.01), FEV1/FVC from 0.65 ± 0.11 to 0.69 ± 0.11 (p < 0.001), and FEF25–75 from 0.84 (0.54–1.15) l/s to 0.99 (0.71–1.53) l/s (p < 0.001). Pulmonary hyperinflation decreased, with RV declining from 2.90 (2.25–3.80) l to 2.50 (1.72–3.20) l (p < 0.0001). DLCOcSB increased from 4.59 ± 1.36 to 4.86 ± 1.53 mmol/min/kPa (p < 0.05). CAT score improved from 25.99 ± 4.03 to 22.93 ± 5.76 (p < 0.0001). The number of moderate/severe exacerbations decreased from 2.08 ± 0.66 to 0.15 ± 0.36, and 63 patients (73%) met the composite criteria for COPD disease stability.ConclusionsIn this real-world cohort of exacerbating patients with COPD, once-daily single-inhaler FF/UMEC/VI was associated with improved lung function, reduced hyperinflation, better symptom control, enhanced quality of life, and a significant reduction in exacerbation frequency. These findings suggest that FF/UMEC/VI may be a useful therapeutic option for supporting multidimensional disease stability in high-risk patients with COPD, although prospective controlled studies are needed to confirm these observations.Keywords: Chronic obstructive pulmonary disease, Triple inhaled therapy, Stability, Exacerbations, Real-world Key Summary Points Why carry out this study?Patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic or experience exacerbations despite maintenance inhaled therapy have a high clinical burden and may benefit from treatment optimization with single-inhaler triple therapy.Although randomized trials have demonstrated the efficacy of inhaled triple therapy, real-world evidence on its impact on multidimensional COPD disease stability remains limited.This study evaluated whether once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was associated with improvements in lung function, symptoms, health status, and exacerbation burden over 12 months in patients with exacerbating COPD.What was learned from the study?In this retrospective real-world cohort, FF/UMEC/VI treatment was associated with improvements in forced expiratory volume in the first second (FEV1), lung volumes, corrected single-breath diffusion lung capacity for carbon monoxide (DLCOcSB), COPD Assessment Test (CAT) score, and a reduction in moderate/severe exacerbations after 12 months.Overall, 63 of 86 patients achieved the composite endpoint of multidimensional disease stability, defined by absence of moderate/severe exacerbations, preservation of FEV1, and no clinically meaningful worsening in CAT score.These findings support the usefulness of multidimensional assessment in routine COPD care, although prospective controlled studies are needed to confirm the role of FF/UMEC/VI in achieving disease stability. Introduction Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition that is typified by persistent, frequently progressive airflow obstruction caused by abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) [1]. These abnormalities can cause dyspnea, cough, sputum production, and/or exacerbations [1]. Although smoking tobacco and breathing in harmful particles and gases from indoor and outdoor air pollution are the primary environmental exposures that cause COPD, additional host and environmental variables (such as aberrant lung development and accelerated lung aging) may also play a role [2]. Several comorbidities can affect the clinical status and prognosis of patients with COPD and may require additional treatment. These coexisting illnesses may resemble an acute exacerbation and/or make it worse [3]. Another important aspect concerns exacerbations. Reducing the harmful effects of the present exacerbation and avoiding future occurrences are the objectives of therapy for COPD exacerbations [4]. In this context, inhaled triple therapy combining an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) has emerged as an important treatment option for patients with symptomatic COPD and a history of exacerbations despite dual bronchodilation [5]. By simultaneously targeting airway inflammation, bronchoconstriction, and dynamic hyperinflation, triple therapy aims to provide more comprehensive control of the disease process than dual combinations, with potential benefits on lung function, symptoms, health status, and exacerbation risk. Several randomized controlled trials have shown that single-inhaler triple therapy can reduce moderate and severe exacerbations and improve lung function and quality of life compared with dual ICS/LABA or LABA/LAMA regimens, particularly in patients at higher risk and/or with evidence of type 2 airway inflammation [6]. Even among patients on inhaled maintenance therapy, the burden of COPD remains high despite notable advancements in its diagnosis and management [7]. Few disease-modifying treatments have been shown to be helpful in considerably slowing the disease’s course in its early stages [8]. Nevertheless, new clinical studies using novel therapies provide certain subgroups with hope for better results. While inhaled therapies remain the cornerstone of COPD management, the therapeutic landscape is expanding: biologic agents, originally developed and approved for asthma, are now being investigated in COPD, reflecting a growing recognition of the role of type 2 inflammation in selected patient subgroups [9, 10]. Among emerging biologic treatments, dupilumab, an interleukin (IL)-4/IL-13 pathway inhibitor, has recently shown significant reductions in COPD exacerbations and improvements in lung function in patients with chronic bronchitis phenotype and evidence of type 2 inflammation, suggesting a potential role for targeted therapy in selected COPD subgroups [11, 12]. However, the extent to which these benefits translate into sustained “disease stability”, as defined by composite criteria that integrate exacerbations, lung function, and patient-reported outcomes, has been less extensively explored in real-world settings. The idea of disease stability may be used to define long-term objectives to stop clinical deterioration and reduce future risk throughout follow-up, along with the possibility of improvement. Disease stability may represent a desirable treatment objective for patients and a target for future disease-modifying strategies. Other chronic inflammatory disorders have established treatment techniques aimed at controlling disease activity, which is defined as the reversible components of the disease [13]. The FULFIL study evaluated lung function and quality of life in patients with COPD treated with fluticasone furoate/ umeclidinium/ vilanterol (FF/UMEC/VI) [14]. A post hoc analysis of this study considered the following criteria to define COPD stable at week 24: no moderate or severe flare-ups, no forced expiratory volume in the first second (FEV1) decline ≥ 100 ml, reduction of at least 4 points in Saint George Respiratory Questionnaire (SGRQ) or 2 points in COPD Assessment Test (CAT) from baseline. Disease stability was maintained with FF/UMEC/VI for a period, on average, five times longer than in patients receiving budesonide/formoterol fumarate (BUD/FOR) [15]. The aim of this retrospective single-center study was to evaluate, in exacerbating patients with COPD, the effects of the single inhaler therapy FF/UMEC/VI on health status, respiratory symptoms, lung function and exacerbation rate, all of which contribute to assess disease stability. Methods In this retrospective single-center study, adult patients suffering from COPD treated with the single inhaler therapy FF/UMEC/VI 92/55/22 µg were evaluated at the Respiratory Unit of “Magna Graecia” University Hospital of Catanzaro, Italy. COPD was diagnosed according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations [1]. Patients were referred to our outpatient respiratory clinic for routine COPD management and treatment optimization because of persistent symptoms and/or a history of moderate or severe exacerbations despite maintenance inhaled therapy. The decision to initiate FF/UMEC/VI was made by the treating physician according to GOLD recommendations and routine clinical practice. In all cases, FF/UMEC/VI was prescribed as a treatment escalation or simplification strategy. All previous inhaled therapies were interrupted at the time of FF/UMEC/VI initiation. Prior inhaled treatments were categorized as LABA/LAMA, ICS/LABA, open triple therapy, or other maintenance regimens. Patients enrolled for this study were classified into group E of GOLD guidelines, which includes exacerbating patients who experienced ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization within the year [1]. FF/UMEC/VI was prescribed in accordance with current eligibility indications, and it was administered at the dosage of one inhalation once daily. Relevant comorbidities were extracted from medical records, with particular attention to cardiovascular disease, metabolic disorders, bronchiectasis, and previous or concomitant asthma diagnosis. Patients with a predominant diagnosis of asthma were not included. Smoking history was collected from baseline medical records and reported descriptively. However, because the distinction between current and former smoking status was not consistently documented for all patients in this retrospective dataset, no formal subgroup analysis comparing active smokers and former smokers was performed. Before the start of the above-mentioned inhaled therapy and after 1 year of treatment, lung function tests were carried out according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines by Master Screen Pulmonary Function Testing System and Master Screen Body (Jaeger, Hannover, Germany) [16]. Measurement of lung diffusing capacity for carbon monoxide (DLCO) was performed as established by ERS/ATS standards for single-breath carbon monoxide uptake in the lung, and its level was corrected for the hemoglobin levels. Thus, diffusion lung capacity was evaluated as corrected single-breath DLCO (DLCOcSB) [17]. In particular, forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced mid expiratory flow between 25 and 75% of FVC (FEF25–75), residual volume (RV), and total lung capacity (TLC) were assessed at baseline and after 1 year of treatment with FF/UMEC/VI. Furthermore, patients completed CAT score, that was used in accordance with applicable terms of use and permission requirements. The number of COPD exacerbations was recorded considering the number of exacerbations within the previous 12 months and 1 year after the beginning of FF/UMEC/VI therapy. Tolerability and drug safety were assessed retrospectively by reviewing medical records, including documentation from routine monthly follow-up telephone calls, during which patients were asked about headache, infections, cough, and gastrointestinal disorders, as well as any worsening in health status. Treatment adherence to FF/UMEC/VI was also evaluated during routine follow-up through review of medical records and monthly telephone contacts, during which patients were specifically asked about regular inhaler use, missed doses, and treatment interruptions. All recruited patients signed a written informed consent. This study was authorized by the Ethics Committee of Calabria Region, Italy (Catanzaro, Italy; document no. 263–July 23, 2020). All participants signed written informed consent forms. The study was performed in accordance with the Declaration of Helsinki and its later amendments. Statistical Analysis Statistical analyses were performed using GraphPad Prism, version 10.3.0 (GraphPad Software Inc., San Diego, CA, USA). Normally distributed data are presented as mean ± standard deviation (SD), whereas non-normally distributed data are presented as median (interquartile range, IQR). Normality was assessed using the Anderson–Darling and Kolmogorov–Smirnov tests. Paired comparisons were performed using a paired t test or the Wilcoxon signed-rank test, as appropriate. In addition, a multivariable logistic regression model was used to estimate adjusted odds ratios (ORs) for baseline variables predicting achievement of COPD stability, and results are reported as ORs with 95% confidence intervals. All tests were two-sided, and a p value < 0.05 was considered statistically significant. Results A total of 86 adult patients with COPD were included in the study, comprising 24 women (28%) and 62 men (72%). The mean age was 72.29 ± 9.20 years, and the median body mass index (BMI) was 30 (26.00–36.50) kg/m2. At baseline, patients exhibited moderate-to-severe airflow limitation, with a mean FEV1 of 54.85 ± 16.47% predicted, and marked static hyperinflation, as indicated by a mean RV of 136.90 ± 62.42% predicted. Baseline characteristics are summarized in Table 1. Table 1Baseline patient characteristicsAge, mean ± SD, years72.29 ± 9.20Male gender, N (%)62 (72)Weight, median (IQR), kg82.00 (73.50–102.50)Height, median (IQR), cm165.00 (160.50–172.00)BMI, median (IQR), kg/m230 (26.00–36.50)Smokers and ex-smokers, N (%)82 (95)CAT, mean ± SD, score25.99 ± 4.03Exacerbations, mean ± SD2.08 ± 0.66On treatment with LAMA/LABA, N (%)80 (93)On treatment with ICS/LABA, N (%)6 (7)CAT chronic obstructive pulmonary disease assessment test, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist Baseline patient characteristics CAT chronic obstructive pulmonary disease assessment test, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist After 12 months of treatment with FF/UMEC/VI, significant improvements in lung function were observed. Mean FEV1 increased from 1.46 ± 0.51 l at baseline to 1.61 ± 0.60 l (p < 0.01), while FEV1/FVC ratio improved from 0.65 ± 0.11 to 0.69 ± 0.11 (p < 0.001), indicating enhanced airflow and reduced obstruction. FVC also showed a significant increase, both in percentage of predicted and absolute values, improving from 2.23 ± 0.72 l to 2.31 ± 0.74 l (p < 0.05), supporting an overall improvement in ventilatory capacity. Small airway function improved as well, with FEF25–75 increasing from 0.84 (0.54–1.15) l/s to 0.99 (0.71–1.53) l/s (p < 0.001). These functional gains were accompanied by a significant reduction in static hyperinflation, as demonstrated by decreases in TLC, from 5.67 ± 1.57 l to 5.13 ± 1.42 l (p < 0.0001), and RV, from 2.90 (2.25–3.80) l to 2.50 (1.72–3.20) l (p < 0.0001). Overall, these changes suggest a more favorable lung mechanics profile, with reduced air trapping and improved ventilatory efficiency. Gas exchange parameters also improved during follow-up. DLCOcSB increased from 4.59 ± 1.36 to 4.86 ± 1.53 mmol/min/kPa (p < 0.05), indicating a modest but significant enhancement in diffusing capacity, potentially reflecting improved ventilation-perfusion matching. Airway functional parameters before and after 1 year of treatment with FF/UMEC/VI are summarized in Table 2. Table 2Airway functional parameters before and after 1 year of treatment with FF/UMEC/VIAirway functional parameterBaselineFollow-upp valueFEV1, mean ± SD, %54.85 ± 16.4761.34 ± 18.910.0002FEV1, mean ± SD, l1.46 ± 0.511.61 ± 0.600.0012FVC, mean ± SD, %64.04 ± 16.0767.36 ± 16.620.0457FVC, mean ± SD, l2.23 ± 0.722.31 ± 0.740.0437FEV1/FVC, mean ± SD0.65 ± 0.110.69 ± 0.110.0002TLC, mean ± SD, %96.44 ± 25.6386.99 ± 21.03 < 0.0001TLC, mean ± SD, l5.67 ± 1.575.13 ± 1.42 < 0.0001RV, mean ± SD, %136.90 ± 62.42118.80 ± 52.13 < 0.0001RV, median (IQR), l2.90 (2.25–3.80)2.50 (1.72–3.20) < 0.0001FEF25-75, mean ± SD, %44.40 ± 27.8657.98 ± 34.86 < 0.0001FEF25-75, median (IQR), l/s0.84 (0.54–1.15)0.99 (0.71–1.53)0.0003DLCOcSB, mean ± SD, %58.79 ± 16.4861.98 ± 19.000.0421DLCOcSB, mean ± SD, mmol/min/kPa4.59 ± 1.364.86 ± 1.530.0250DLCOcSB corrected single-breath diffusion lung capacity for carbon monoxide, FEF25-75 forced mid expiratory flow between 25 and 75% of forced vital capacity, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, RV residual volume, TLC total lung capacity Airway functional parameters before and after 1 year of treatment with FF/UMEC/VI DLCOcSB corrected single-breath diffusion lung capacity for carbon monoxide, FEF25-75 forced mid expiratory flow between 25 and 75% of forced vital capacity, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, RV residual volume, TLC total lung capacity These physiological improvements were paralleled by clinically meaningful benefits in patient-reported outcomes. After 12 months of therapy, CAT score significantly decreased from 25.99 ± 4.03 to 22.93 ± 5.76 (p < 0.0001), indicating improved symptom control and health status. In addition, the number of moderate or severe exacerbations markedly declined from 2.08 ± 0.66 in the year prior to treatment to 0.15 ± 0.36 during follow-up (p < 0.0001), confirming a substantial reduction in exacerbation burden. Consistently, the median number of moderate/severe exacerbations decreased from 2 (2–3) in the 12 months before FF/UMEC/VI initiation to 0 (0–0) during the 12-month follow-up, confirming a marked reduction in exacerbation burden after treatment initiation. Importantly, when considering a multidimensional definition of COPD disease stability, defined as the absence of moderate/severe exacerbations, no clinically relevant worsening in symptoms (CAT increase ≤ 2 points), and no significant decline in lung function (defined as no FEV1 reduction ≥ 100 ml), 63 patients (73%) achieved disease stability after 12 months of FF/UMEC/VI therapy (Fig. 1). These findings highlight the ability of single-inhaler triple therapy to simultaneously impact multiple clinically relevant domains (Fig. 2). Multidimensional assessment of COPD disease stability after 12 months of FF/UMEC/VI treatment. CAT chronic obstructive pulmonary disease assessment test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in the first second, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol Twelve-month effects of FF/UMEC/VI on FEV1 (A), CAT score (B), and exacerbations (C). CAT chronic obstructive pulmonary disease assessment test, FEV1 forced expiratory volume in the first second, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol In the exploratory multivariable logistic regression analysis, baseline physiological parameters were associated with the probability of achieving the composite disease stability endpoint. Specifically, lower baseline RV% (OR = 0.99; p < 0.05) and TLC% (OR = 0.97; p < 0.01), along with higher DLCO% (OR = 1.04; p < 0.05), were significantly associated with a greater likelihood of achieving stability. These results suggest that patients with less severe hyperinflation and better preserved gas transfer are more likely to benefit from treatment and achieve sustained clinical stability (Fig. 3). By contrast, blood eosinophils were not significantly associated with achievement of COPD disease stability after 12 months of FF/UMEC/VI treatment. Forest plot of adjusted odds ratios (OR) for variables associated with COPD stability attainment after 12 months of therapy with FF/UMEC/VI. Predictors that favor COPD stability are highlighted in green, whereas those with a negative impact are shown in red; black variables are not statistically significant. CAT chronic obstructive pulmonary disease assessment test, COPD chronic obstructive pulmonary disease, DLCOcSB corrected single-breath diffusion lung capacity for carbon monoxide, FEV1 forced expiratory volume in the first second, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, RV residual volume, TLC total lung capacity Overall, 82 patients were classified as current or former smokers, whereas 4 patients were never smokers. A reliable current-versus-former smoker subgroup analysis could not be performed because detailed smoking-status information was not uniformly available across the retrospective records. During follow-up, no persistent treatment discontinuation due to adverse events or poor tolerability was documented in the available clinical records. Monthly telephone contacts suggested overall regular use of FF/UMEC/VI in most patients. Discussion In this retrospective single-center study, among exacerbating patients with COPD (≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization within the year, group E according to GOLD), once-daily single-inhaler triple therapy with fluticasone furoate, umeclidinium, and vilanterol was associated with a lower rate of moderate or severe COPD exacerbations, as well as improved lung function, respiratory symptoms and health-related quality of life, all of which are relevant to the assessment of disease stability and long-term disease progression. Because the study was uncontrolled and observational, these findings should be interpreted as associations observed after treatment initiation rather than as definitive evidence of causality. Our results are consistent with and extend evidence from large phase III randomized controlled trials of single-inhaler triple therapy. In FULFIL, FF/UMEC/VI demonstrated clinically meaningful and statistically significant improvements in trough FEV1 and SGRQ scores, and reduced exacerbation rates compared with BUD/FOR in symptomatic patients with COPD at risk of exacerbations [14]. The IMPACT trial confirmed that once-daily FF/UMEC/VI significantly lowered the rate of moderate/severe exacerbations and improved lung function and health status compared with FF/VI or UMEC/VI in a broad population of patients with symptomatic COPD and a history of exacerbations [5, 18]. Similarly, the ETHOS trial showed that triple therapy with budesonide/glycopyrrolate/formoterol reduced moderate/severe exacerbation rates and, in secondary analyses, all-cause mortality compared with dual bronchodilation or ICS/LABA [19]. Additional programs evaluating extra-fine BDP/FF/G in the TRIBUTE, TRILOGY and TRINITY studies also reported improved lung function and reductions in exacerbations versus ICS/LABA, LAMA alone or LABA/LAMA [20–22]. Our real-world findings align with this body of trial evidence and may suggest that the benefits of triple therapy are reproducible in everyday clinical practice when previous inhaled regimens are completely withdrawn. The physiological changes observed in our population provide insight into mechanisms underpinning these clinical effects. FF/UMEC/VI significantly reduced static hyperinflation (decreases in TLC and RV), a key determinant of exertional dyspnea and exercise tolerance. Improvements in FEV1/FVC and FEF25–75 indicate better patency of both large and small airways and a more homogeneous ventilation pattern. These findings are consistent with spirometric and plethysmographic improvements reported for FF/UMEC/VI in FULFIL and IMPACT and for other triple combinations such as BDP/FF/G in TRILOGY/TRINITY/TRIBUTE [5, 20–22]. The observed increase in DLCOcSB may reflect improved ventilation–perfusion matching and recruitment of previously under-ventilated lung units. Pharmacologically, these effects are plausible given the complementary actions of a LAMA and LABA on bronchomotor tone and dynamic hyperinflation, combined with the anti-inflammatory properties of ICS, particularly in patients with an eosinophilic or type 2 inflammatory component. The functional changes observed in our cohort were associated with improvements in patient-reported outcomes, although the uncontrolled study design does not allow us to establish a causal relationship. CAT score improved beyond established minimal clinically important difference thresholds, indicating better symptom control and health status. Comparable improvements in health-related quality of life with FF/UMEC/VI have been reported in FULFIL and in several real-world studies and non-interventional programs such as ELLITHE, where 12 months of FF/UMEC/VI therapy led to sustained reductions in CAT score [23]. In our population, the reduction in moderate/severe exacerbations during the year of treatment confirms the protective effect consistently seen with triple therapy in RCTs and real-world cohorts treated with FF/UMEC/VI [24–26]. Because exacerbations are major drivers of accelerated lung function decline, impaired quality of life, hospitalization, and mortality, their prevention is central to modifying the long-term trajectory of COPD. The concept of “disease stability” has recently gained prominence as a meaningful treatment goal in chronic inflammatory diseases. In COPD, composite definitions that integrate exacerbation risk, FEV1 decline, and health-status deterioration may better capture the overall disease trajectory than single endpoints. A post hoc analysis of FULFIL introduced a composite endpoint of clinical stability (absence of moderate/severe exacerbations, no FEV1 decline ≥ 100 ml, and clinically important improvements in SGRQ or CAT), showing that FF/UMEC/VI maintained stability for a substantially longer period than BUD/FOR [15]. Our data support the feasibility of applying such composite concepts in clinical practice: over 12 months, patients on FF/UMEC/VI showed stable FEV1, improved symptoms and reduced exacerbations, suggesting that triple therapy can help achieve and maintain this broader notion of disease stability, as previously investigated in other real-world clinical studies [27–29]. COPD disease stability is closely related to the framework of clinically important deterioration (CID), as both constructs integrate lung function, symptoms/health status, and exacerbations. However, whereas CID identifies clinically meaningful worsening, disease stability focuses on the absence of deterioration and the maintenance or improvement of these domains over time. Accordingly, our composite endpoint (no moderate/severe exacerbations, no FEV1 decline ≥ 100 ml, and no clinically meaningful worsening in CAT score) was intended as a CID-aligned, multidimensional measure of clinical stability. Nevertheless, because disease stability has not yet been fully validated as a standardized COPD outcome, our findings should be interpreted as an exploratory real-world application of this concept. From a practical perspective, the use of a single inhaler may also contribute to the benefits observed. Beyond potential regimen simplification, health-economic evaluations suggest that FF/UMEC/VI may represent a cost-effective treatment option in COPD, driven by reductions in exacerbation-related healthcare utilization and associated costs [30]. In our study, all previous inhaled therapies were stopped, and patients were switched to once-daily FF/UMEC/VI, a strategy similar to that used in several real-world pre–post analyses where initiation of FF/UMEC/VI reduced exacerbations and healthcare resource use in patients previously treated with ICS/LABA or dual bronchodilation [24]. In our cohort, 63 patients (73%) met our prespecified composite definition of COPD stability—no moderate/severe exacerbations, no clinically meaningful symptom worsening (CAT increase ≤ 2 points), and no clinically relevant decline in lung function (FEV1 drop ≤ 100 ml from baseline). This multidimensional endpoint is consistent with the concept of “disease stability” proposed by Singh et al., who emphasize integrating exacerbations, health status (SGRQ or CAT), and lung function over a 6–12-month interval, using MCID-based thresholds that overlap with those adopted in the clinically important deterioration (CID) framework (e.g., CAT > 2 and FEV1 > 100 ml) [31]. Compared with the clinical control rates discussed by Singh et al. (60% in mild-to-moderate COPD and 30% in more severe populations), the 73% stability rate observed in our study appears favorable, although direct comparisons are limited by differences in definitions and populations. Notably, Singh et al. also report that, with treatment optimization, > 50% of high-risk frequent exacerbators can remain exacerbation-free over 1 year; our results extend this observation by showing that a substantial proportion also maintained stable symptoms and FEV1 within a composite stability construct [31]. The multivariable logistic regression analysis of our results also showed that higher DLCO %, as well as lower baseline RV % and TLC %, were associated with COPD stability attainment after 12 months of treatment with FF/UMEC/VI. Our results could be interpreted in the context of the emerging literature on predictors of COPD stability. In a large prospective longitudinal cohort, Loo et al. defined clinical stability as the absence of exacerbations together with stable symptoms (CAT change < 2 points) and reported that approximately one-third of patients achieved stability at 1–2 years. In that study, predictors of 2-year stability were predominantly clinical and easily accessible variables, including higher BMI, higher post-bronchodilator FEV1/FVC ratio, fewer baseline exacerbations, absence of bronchiectasis, preserved hemoglobin levels, and smoking cessation [32]. Our results are conceptually complementary to those of Loo et al.: preserved gas transfer (higher DLCO%) may reflect a lower emphysema/vascular burden and a greater capacity to maintain clinical stability, whereas lower RV% and TLC% indicate less static hyperinflation and air trapping. In our cohort, eosinophils were not associated with the achievement of disease stability. This finding may be related to the limited sample size, the composite nature of the stability endpoint, and the fact that disease stability integrated not only exacerbation prevention but also lung function preservation and symptom control. Our findings should also be interpreted in the context of emerging therapeutic options. While inhaled triple therapy remains the backbone for patients with persistent symptoms and/or exacerbations, biologic agents targeting type 2 inflammation, such as dupilumab, have recently shown significant reductions in exacerbation rates and improvements in lung function in selected COPD populations with chronic bronchitis phenotype and evidence of type 2 inflammation [11, 12]. In this evolving landscape, single-inhaler triple therapy such as FF/UMEC/VI may represent the optimal background treatment onto which targeted biologics can be added in appropriate patients. Future studies integrating physiological data, biomarkers, and treatable traits (e.g., eosinophilic inflammation, chronic bronchitis, frequent exacerbator phenotype) will be essential to refine the concept of disease stability and personalized therapy. Our findings are also consistent with the growing body of real-world evidence from observational studies and non-interventional cohorts evaluating fixed-dose single-inhaler triple therapy in COPD. Although ORESTES and EROS investigated a different single-inhaler triple combination, namely budesonide/glycopyrronium/formoterol fumarate, these large real-world studies have contributed to confirming, outside the controlled setting of randomized clinical trials, that initiation of or switching to fixed triple therapy may be associated with clinically relevant benefits in routine practice, including reductions in exacerbation burden, healthcare resource utilization, and treatment complexity [33, 34]. Furthermore, retrospective real-life data in persistent users of budesonide/glycopyrronium/formoterol fumarate suggest sustained reductions in exacerbations and rescue medication use, together with improvements in lung function, supporting the relevance of treatment persistence and adherence in maximizing the benefits of single-inhaler triple therapy [35]. Real-world evidence is also available for the extrafine fixed triple combination of beclomethasone dipropionate/formoterol fumarate/glycopyrronium. In the TRICOP non-interventional study, 52 weeks of treatment with this combination were associated with significant improvements in lung function, symptom control, CAT score, and reductions in moderate and severe exacerbations [36]. Similarly, TRITRIAL showed that beclomethasone dipropionate/formoterol fumarate/glycopyrronium was effective and well tolerated in patients with moderate-to-severe COPD and poorly controlled disease, improving health-related quality of life, sleep quality, treatment adherence, and inhaler usability, while reducing COPD symptoms and exacerbation risk in a real-life setting [37]. More recently, the MASCOT prospective observational study showed early improvements in small-airway dysfunction and health status after switching from LABA/LAMA to beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD and small-airway impairment [38]. In line with this broader real-world evidence on fixed single-inhaler triple therapy, our study showed improvements in CAT score and exacerbation burden after 12 months of FF/UMEC/VI treatment. Importantly, our study specifically evaluated FF/UMEC/VI and provides a more detailed physiological characterization, including not only spirometric parameters but also lung volumes and DLCOcSB. This allowed us to explore the physiological components of treatment response, particularly changes in airflow limitation, static hyperinflation, and gas transfer. Moreover, our study extends previous real-world evidence by applying a multidimensional disease stability endpoint integrating functional preservation, symptom/health-status stability, and exacerbation prevention. Therefore, although limited by its retrospective single-center design and smaller sample size, our study adds complementary information by linking the clinical benefits of FF/UMEC/VI to a broader physiological and composite stability framework. Several limitations of this study must be acknowledged. Its retrospective design and lack of a control group preclude causal inference and may introduce selection and information bias. The single-center setting and sample size of 86 patients may limit generalizability to wider COPD populations with different ethnic or comorbidity profiles. Exacerbation history in the 12 months prior to FF/UMEC/VI initiation partly relied on medical records and patient recall, which may underestimate baseline exacerbation burden. We did not systematically collect blood eosinophils or other biomarkers of type 2 inflammation, preventing identification of subgroups with potentially greater benefit from ICS-containing triple therapy. Finally, the follow-up period was limited to 12 months; therefore, we cannot determine whether the observed stability is sustained beyond 12 months. Nevertheless, our findings are consistent with prospective real-world cohort data and post hoc responder analyses of FF/UMEC/VI reporting clinically meaningful benefits over a 12-month timeframe [39, 40]. In addition, although smoking history was available for the overall cohort, detailed and consistently recorded information distinguishing current from former smokers, including smoking intensity and cessation timing, was not available for all patients; therefore, the potential influence of active smoking on treatment response could not be specifically assessed. Furthermore, because of the retrospective design and limited sample size, data were not disaggregated by sex, and sex-stratified outcome analyses were not performed, in order to avoid underpowered analyses and overinterpretation. Therefore, potential sex-related differences in treatment response to FF/UMEC/VI could not be assessed and should be investigated in larger prospective studies. Despite these limitations, our study has several strengths, including the real-world design, the comprehensive assessment of lung function (spirometry, lung volumes and DLCOcSB), and parallel evaluation of symptoms, health status and exacerbations. The concordance between physiological and patient-centered outcomes reinforces the clinical relevance of the findings and aligns them with results from major clinical trials and observational cohorts of triple therapy. Conclusions In conclusion, this retrospective single-center study supports the clinical benefit of once-daily single-inhaler triple therapy with FF/UMEC/VI in a COPD population enriched with exacerbating patients, who are typically at higher risk of mortality and faster disease progression. After 12 months of treatment, we observed clinically meaningful improvements in pulmonary function, including increases in FEV1, FVC, FEF25–75, and DLCOcSB, together with a significant reduction in RV, consistent with a decrease in lung hyperinflation. Symptom burden also improved, as reflected by a reduction in CAT score. Importantly, treatment was associated with a significant decline in exacerbation rates, suggesting a relevant impact on overall health status and quality of life. However, because of the retrospective uncontrolled design, limited sample size, incomplete biological characterization, and lack of systematic adherence assessment, these findings should be interpreted cautiously. Further prospective controlled studies incorporating blood eosinophils, comorbidity profiling, smoking-status subgroups, adherence measures, and validated stability endpoints are needed to confirm these observations and refine the role of FF/UMEC/VI in achieving multidimensional disease stability in COPD. Acknowledgements We thank the participants of the study. Medical Writing/Editorial Assistance The authors verify and take full responsibility for the use of generative AI in the preparation of this manuscript. During the preparation of this work, the authors used ChatGPT (version GPT-5.5, OpenAI, San Francisco, CA, USA) in order to enhance readability and language of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Author Contributions Chiara Lupia contributed to data acquisition, data interpretation, and drafting of the manuscript. Daniela Pastore contributed to data acquisition, literature review, and manuscript drafting. Antonio Giacalone contributed to data acquisition and clinical interpretation of the findings. Federica Marrelli contributed to data collection and organization of the clinical dataset. Lucia Novelli contributed to data acquisition and review of the manuscript. Debbie Riccelli contributed to data acquisition and manuscript revision. Angelantonio Maglio contributed to clinical interpretation and critical revision of the manuscript. Giuseppe Armentaro contributed to data interpretation and critical revision of the manuscript. Angela Sciacqua contributed to study supervision and critical revision of the manuscript. Alessandro Vatrella contributed to study supervision, interpretation of the findings, and critical revision of the manuscript. Girolamo Pelaia contributed to study conception and design, supervision, interpretation of the findings, and critical revision of the manuscript. Corrado Pelaia contributed to study conception and design, statistical analysis, data interpretation, drafting and critical revision of the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. Funding No financial support was received for the research and/or publication of this article. Data Availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Conflict of interest Chiara Lupia has nothing to disclose. Daniela Pastore has nothing to disclose. Antonio Giacalone has nothing to disclose. Federica Marrelli has nothing to disclose. Lucia Novelli has nothing to disclose. Debbie Riccelli has nothing to disclose. Angelantonio Maglio has nothing to disclose. Giuseppe Armentaro has nothing to disclose. Angela Sciacqua has nothing to disclose. Alessandro Vatrella has nothing to disclose. Girolamo Pelaia has nothing to disclose. Corrado Pelaia is an Editorial Board member of Pulmonary Therapy. Corrado Pelaia was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Corrado Pelaia has nothing else to disclose. Ethical Approval This study was authorized by the Ethics Committee of Calabria Region, Italy (Catanzaro, Italy; document no. 263–July 23, 2020). All participants signed written informed consent forms. The study was performed in accordance with the Declaration of Helsinki and its later amendments. References Associated Data Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.